Before the recent approval of Eucrisa® (crisaborole), there had been no new drugs approved for atopic dermatitis for more than 15 years and based on successful Phase 3 studies, Pfizer acquired the company that developed Eucrisa® (Anacor Pharmaceuticals Inc.) for US$5.2bn in May 2016. Clinical studies showed that Eucrisa® had little to no impact on itch, which remains a key unmet need fora topic dermatitis patients.
BOT Acquisition will happen, it's inevitable.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
-0.005(2.94%) |
Mkt cap ! $323.5M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 18.0¢ | 16.0¢ | $3.657M | 21.63M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 180978 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 529694 | 12 |
View Market Depth
| Last trade - 16.18pm 28/07/2025 (20 minute delay) ? |
| BOT (ASX) Chart |